AstraZeneca | Investor Day Presentation Deck | 42 slides

AstraZeneca · 2022-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

42
every slide · same image gating as the playbook
01
Slide 1
front_matter
Open slide detailBeat · Attention
02
other
Open slide detailBeat · Attention
03
introduce_nominees
Open slide detailBeat · Attention
04
front_matter
Open slide detailBeat · Attention
05
transition
Open slide detailBeat · Need
06
The diagram uses a circular flow representing 'Ignore axis' and 'Defend axis' strategies in cancer treatment.present_framework
Open slide detailBeat · Need
07
The slide summarizes clinical trial presentation activity at a specific medical conference.summarize
Open slide detailBeat · Need
08
Includes scatter plot (A) and box plot (B) for T-cell proliferation data, plus summary statistics for biliary tract cancer trial.analyze_data
Open slide detailBeat · Need
09
The slide features a stylized silhouette of a human torso with molecular/cellular imagery, likely representing the mechanism of action.transition
Open slide detailBeat · Satisfaction
10
The slide uses a standard clinical trial flow diagram (randomization process).present_framework
Open slide detailBeat · Satisfaction
11
Clinical trial baseline characteristics table.analyze_data
Open slide detailBeat · Satisfaction
12
Includes landmark survival rates at 12, 18, and 24 months and time-dependent hazard ratios.analyze_data
Open slide detailBeat · Satisfaction
13
Includes a table of hazard ratios and p-values, and a risk table at the bottom.analyze_data
Open slide detailBeat · Satisfaction
14
Includes Kaplan-Meier plot for DoR and summary tables for ORR and DoR metrics.analyze_data
Open slide detailBeat · Satisfaction
15
Clinical trial safety data table.analyze_data
Open slide detailBeat · Satisfaction
16
The slide uses a dark blue callout box to emphasize the final conclusion/takeaway.summarize
Open slide detailBeat · Satisfaction
17
The slide features a stylized silhouette of a human head and torso with internal biological imagery.transition
Open slide detailBeat · Satisfaction
18
The slide uses a standard clinical trial flow diagram (CONSORT-style).present_framework
Open slide detailBeat · Satisfaction
19
The slide presents clinical trial baseline data for three cohorts.analyze_data
Open slide detailBeat · Satisfaction
20
Clinical trial data visualization (Kaplan-Meier plot).analyze_data
Open slide detailBeat · Satisfaction
21
Includes a landmark analysis at 9 months for hazard ratios.analyze_data
Open slide detailBeat · Satisfaction
22
Clinical trial data presentation showing PFS, HR, and TTP metrics.analyze_data
Open slide detailBeat · Satisfaction
23
Clinical trial safety data comparing combination therapy vs monotherapy vs standard of care.analyze_data
Open slide detailBeat · Satisfaction
24
The table displays both 'All grades' and 'Grade ≥3' adverse events for specific medical conditions.analyze_data
Open slide detailBeat · Satisfaction
25
summarize
Open slide detailBeat · Satisfaction
26
The slide features a stylized silhouette of a person with an internal biological/molecular visualization.transition
Open slide detailBeat · Action
27
Uses a before-after framing to contrast the status quo (problem) with the new clinical solution.frame_problem
Open slide detailBeat · ActionLoop · Cost Of Inaction
28
The slide uses a three-column layout to contrast the unmet need, the treatment mechanism, and the clinical outcomes.summarize
Open slide detailBeat · ActionLoop · Before After
29
The slide features a stylized silhouette of a human figure with internal biological/molecular imagery.transition
Open slide detailBeat · Action
30
The chart uses a bar chart for existing presence and a stacked bar for GI cancer segments.size_opportunity
Open slide detailBeat · Action
31
The slide uses a split-layout to contrast established late-stage assets (Imfinzi, Enhertu) with early-stage pipeline candidates.summarize
Open slide detailBeat · Action
32
The slide features a stylized silhouette of a person with biological/molecular imagery inside, suggesting a life sciences or medical context.transition
Open slide detailBeat · Action
35
transition
36
The chart displays hazard ratios with 95% confidence intervals for different demographic and clinical categories.analyze_data
37
The slide includes a technical explanation of the TAP score methodology using the Ventana PD-L1 (SP263) Assay.analyze_data
38
analyze_data
39
transition
40
The plot visualizes subgroup analysis for a clinical trial, indicating treatment efficacy across different patient demographics and clinical characteristics.analyze_data
41
analyze_data
42
front_matter